Worldwide atrial fibrillation market products and practices are rising at a CAGR of around 13 percent and are estimated to achieve a size of about USD 16 billion by 2020. Atrial fibrillation is a kind of cardiac arrhythmia and is identified by an irregular cardiac rhythm. This kind of a rhythm is due to a problem in the electrical system of the heart.
Atrial fibrillation is one among several other normally prevalent cardiac rhythm disorders. It is a disease that is dangerous and costly to treat. The general system of healthcare pays a lot of importance on the treatment of this condition.
The atrial fibrillation market is studied from the perspective of different non-pharmalogical and pharmalogical products for the treatment of this disease. The atrial fibrillation market is pushed ahead by increasing cases of strokes, brain damage and atrial fibrillation, owing to blood clots along with increasing geriatric population. The entire atrial fibrillation market with respect to income in 2013 was dominated by pharmalogical products. Few other factors also drive the atrial fibrillation market. These are the inclusion of technical developments in microwave catheter ablation and radiofrequency. Also, comparative reasonable rates of products and application of anti-coagulants as an additional therapy to non-pharmalogical methods drive the market ahead.
Treatment For AF
The pharmalogical market for treating AF includes two kinds of drugs. These are anti-coagulants and anti-arrhythmics. The non-pharmalogical atrial fibrillation market is inclusive of techniques, like maze surgery, catheter ablation and electric cardioversion.
The main techniques of catheter ablation comprise high intensity focused ultrasound, radiofrequency, microwave ablation, cryoablation and laser catheter ablation. The section of radiofrequency catheter ablation will rise at the highest CAGR of more than 15 percent in the next 6 years.
The requirement for non-pharmalogical treatments is driven by minor incisions, reduced invasiveness and quicker recuperation times of catheter ablation. The standard technique for treating AF is medicines to decrease the rate of heart and make it achieve a regular sinus rhythm.
Preventing lifestyle diseases, like high blood pressure and obesity also helps in combating the illness. High blood pressure may be caused by excessive stress. So, avoiding stress is of paramount significance in preventing atrial fibrillation.
Maze surgery had the second biggest share in the non-pharmalogical market for treatment. The pharmalogical market was dominated by anti-coagulants.
The worldwide atrial fibrillation market is divided into various regions. The important regions are Europe, North America, Asia Pacific and the rest of the world. The biggest share of the market was occupied by North America and made up for more than 42 percent of the income of the world in 2013.
Quality reimbursement structures and easy availability of non-pharmalogical techniques in the atrial fibrillation market contribute to this big share. Asia Pacific will rise at a maximum CAGR of more than 15 percent during the forecast period.
The link, http://www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry can be referred to, in order to know more about the atrial fibrillation market. This link provides trends and detailed analysis of the said market.